hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder
carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2,
single-arm proof-of-concept trial: ARCADIA study
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano